Literature DB >> 9811860

Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

K Will1, G Warnecke, L Wiesmüller, W Deppert.   

Abstract

Mutant, but not wild-type p53 binds with high affinity to a variety of MAR-DNA elements (MARs), suggesting that MAR-binding of mutant p53 relates to the dominant-oncogenic activities proposed for mutant p53. MARs recognized by mutant p53 share AT richness and contain variations of an AATATATTT "DNA-unwinding motif," which enhances the structural dynamics of chromatin and promotes regional DNA base-unpairing. Mutant p53 specifically interacted with MAR-derived oligonucleotides carrying such unwinding motifs, catalyzing DNA strand separation when this motif was located within a structurally labile sequence environment. Addition of GC-clamps to the respective MAR-oligonucleotides or introducing mutations into the unwinding motif strongly reduced DNA strand separation, but supported the formation of tight complexes between mutant p53 and such oligonucleotides. We conclude that the specific interaction of mutant p53 with regions of MAR-DNA with a high potential for base-unpairing provides the basis for the high-affinity binding of mutant p53 to MAR-DNA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811860      PMCID: PMC24879          DOI: 10.1073/pnas.95.23.13681

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

2.  Biological significance of unwinding capability of nuclear matrix-associating DNAs.

Authors:  J Bode; Y Kohwi; L Dickinson; T Joh; D Klehr; C Mielke; T Kohwi-Shigematsu
Journal:  Science       Date:  1992-01-10       Impact factor: 47.728

3.  Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein.

Authors:  O Foord; N Navot; V Rotter
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

4.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.

Authors:  S Deb; C T Jackson; M A Subler; D W Martin
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

6.  Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.

Authors:  Y Sun; K Nakamura; E Wendel; N Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.

Authors:  J Y Chen; W D Funk; W E Wright; J W Shay; J D Minna
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

8.  Specific and complex interactions of murine p53 with DNA.

Authors:  S N Weissker; B F Müller; A Homfeld; W Deppert
Journal:  Oncogene       Date:  1992-10       Impact factor: 9.867

9.  p53 increases experimental metastatic capacity of murine carcinoma cells.

Authors:  J Pohl; N Goldfinger; A Radler-Pohl; V Rotter; V Schirrmacher
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  p53-catalyzed annealing of complementary single-stranded nucleic acids.

Authors:  P Oberosler; P Hloch; U Ramsperger; H Stahl
Journal:  EMBO J       Date:  1993-06       Impact factor: 11.598

View more
  22 in total

1.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Authors:  S Donzelli; G Fontemaggi; F Fazi; S Di Agostino; F Padula; F Biagioni; P Muti; S Strano; G Blandino
Journal:  Cell Death Differ       Date:  2011-12-23       Impact factor: 15.828

Review 2.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 3.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

4.  Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development.

Authors:  Shanshan Wang; Qian Hao; Jiajia Li; Yajie Chen; Hua Lu; Xiaohua Wu; Xiang Zhou
Journal:  Genes Dis       Date:  2020-11-21

Review 5.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05

Review 6.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

Review 7.  Tumor suppressor p53 and its gain-of-function mutants in cancer.

Authors:  Juan Liu; Cen Zhang; Zhaohui Feng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

8.  BCL7C suppresses ovarian cancer growth by inactivating mutant p53.

Authors:  Canhua Huang; Qian Hao; Getao Shi; Xiang Zhou; Yu Zhang
Journal:  J Mol Cell Biol       Date:  2021-05-07       Impact factor: 6.216

9.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

10.  Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.

Authors:  Marie Brázdová; Lucie Navrátilová; Vlastimil Tichý; Kateřina Němcová; Matej Lexa; Roman Hrstka; Petr Pečinka; Matej Adámik; Borivoj Vojtesek; Emil Paleček; Wolfgang Deppert; Miroslav Fojta
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.